A Drug Safety Controversy Continues: Whether It Is The Diabetes Drug OrThe Diabetes Which Causes Pancreas Disease
As regards the possible association between Victoza and pancreatitis as a side effect of this diabetes drugfrom Novo Nordisk, there have quite a few assorted developments during the period April 2011 to April2012. In order to get those all out in front of us, and so as to see how this drug safety issue emerged andwhere it may be headed going forward, we offer the following time-line of sorts.
The Annals of Pharmacotherapy
The British Medical Journal
),letters written by Merck and Novo Nordisk to Anil Rustgi, the editor-in-chief of
, resulted in that journal withdrawing an article which it had posted on itswebsite about how Januvia (sitagliptin) and Byetta (exenatide) have been associated withan increased risk of pancreatitis as well as several cancers.From this April 2011
The diabetes drug Januvia is marketed by Merck.Byetta is marketed by Amylin Pharmaceuticals and Eli Lilly.Novo Nordisk has a relatively new diabetes drug, Victoza (approved by FDA in 2010),which is in the same class of drugs as Byetta. Victoza (liraglutide) has been linked topancreatitis, also.